0.4383
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché CTSO Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$0.477
Aprire:
$0.4627
Volume 24 ore:
145.40K
Relative Volume:
0.99
Capitalizzazione di mercato:
$27.52M
Reddito:
$37.20M
Utile/perdita netta:
$-11.85M
Rapporto P/E:
-2.2972
EPS:
-0.1908
Flusso di cassa netto:
$-10.59M
1 W Prestazione:
+12.93%
1M Prestazione:
-8.50%
6M Prestazione:
-32.04%
1 anno Prestazione:
-62.22%
Cytosorbents Corp Stock (CTSO) Company Profile
Nome
Cytosorbents Corp
Settore
Industria
Telefono
973-329-8885
Indirizzo
305 COLLEGE ROAD EAST, PRINCETON, NJ
Compare CTSO vs ABT, SYK, MDT, BSX, EW
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
|
CTSO
Cytosorbents Corp
|
0.4383 | 27.52M | 37.20M | -11.85M | -10.59M | -0.1908 |
|
ABT
Abbott Laboratories
|
88.41 | 153.99B | 45.13B | 6.28B | 7.38B | 3.5895 |
|
SYK
Stryker Corp
|
307.80 | 118.00B | 25.27B | 3.34B | 4.57B | 8.6334 |
|
MDT
Medtronic Plc
|
79.34 | 101.86B | 36.36B | 4.84B | 5.43B | 3.7212 |
|
BSX
Boston Scientific Corp
|
45.29 | 67.32B | 20.62B | 3.56B | 3.48B | 2.3847 |
|
EW
Edwards Lifesciences Corp
|
87.36 | 50.30B | 6.30B | 1.07B | 1.09B | 1.8406 |
Cytosorbents Corp Stock (CTSO) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2023-09-07 | Iniziato | B. Riley Securities | Buy |
| 2021-10-14 | Ripresa | B. Riley Securities | Buy |
| 2020-09-17 | Iniziato | Jefferies | Buy |
| 2020-09-01 | Iniziato | SVB Leerink | Outperform |
| 2017-08-08 | Reiterato | Maxim Group | Buy |
| 2016-10-26 | Iniziato | Aegis Capital | Buy |
| 2016-05-24 | Iniziato | Maxim Group | Buy |
| 2015-10-29 | Aggiornamento | WBB Securities | Speculative Buy → Buy |
| 2015-05-12 | Reiterato | MLV & Co | Buy |
| 2015-04-01 | Reiterato | MLV & Co | Buy |
| 2015-03-05 | Iniziato | MLV & Co | Buy |
| 2015-02-25 | Iniziato | WBB Securities | Speculative Buy |
| 2015-01-27 | Reiterato | H.C. Wainwright | Buy |
Mostra tutto
Cytosorbents Corp Borsa (CTSO) Ultime notizie
CytoSorbents to Present at the Life Sciences Forum on June 24, 2026 and Meet Virtually with Investors on June 30, 2026 - Yahoo Finance
Cytosorbents Corp (CTSO) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Cytosorbents Corp (CTSO) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Cytosorbents Corp (CTSO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Cytosorbents Corp (CTSO) Institutional Confidence - TradingKey
Cytosorbents Corp (CTSO) Valuation: PE, PB & Fair Value Analysis - TradingKey
Cytosorbents Corp (CTSO) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Cytosorbents Corp (CTSO) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Cytosorbents Corp (CTSO) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Cytosorbents Corp (CTSO) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Cytosorbents CFO Peter Mariani buys $44,000 in stock - Investing.com UK
Cytosorbents CFO Peter Mariani buys $44,000 in stock By Investing.com - Investing.com India
Cytosorbents (CTSO) CFO Peter Mariani buys 100,000 shares in open market - Stock Titan
Cytosorbents CEO Phillip Chan buys $104,897 in company stock - Investing.com
CTSO | Cytosorbents Corp. FinancialsIncome Statement - Quiver Quantitative
Cytosorbents (CTSO) CEO boosts stake with 261,469-share open-market buy - Stock Titan
Cytosorbents Corporation (NASDAQ:CTSO): Is Breakeven Near? - simplywall.st
CytoSorbents (NASDAQ: CTSO) asks shareholders to OK 1-for-5–1-for-20 reverse split - Stock Titan
CytoSorbents Corp stock (US23283M1018): Q1 miss keeps focus on growth and cash runway - AD HOC NEWS
CTSO Technical Analysis & Stock Price Forecast - Intellectia AI
CytoSorbents Corp stock (US23283M1018): analyst sentiment and low share price keep focus on Nasdaq-l - AD HOC NEWS
CytoSorbents Corp stock (US23283M1018): Nasdaq price action and valuation metrics in focus - AD HOC NEWS
Cytosorbents Earnings Call Balances Progress and Pressure - The Globe and Mail
Why Cytosorbents (CTSO) Just Dropped -1.78% — What to Watch 2026-05-20Expert Momentum Signals - Newser
Earnings call transcript: CytoSorbents Q1 2026 misses forecasts, stock falls - Investing.com
Cytosorbents (CTSO) Q1 2026 Disappoints — EPS $-0.08 Below $-0.06 ViewsDividend Growth Analysis - Newser
Cytosorbents Corporation (NASDAQ:CTSO) Q1 2026 Earnings Call Transcript - Insider Monkey
Cytosorbents Earnings Call Balances Progress And Pressure - The Globe and Mail
CytoSorbents Corp (CTSO) Q1 2026 Earnings Call Highlights: Navigating Challenges with Strategic Growth - GuruFocus
Is CytoSorbents (CTSO) a Value Trap Despite 39.9% Undervaluation - GuruFocus
CytoSorbents (CTSO) Reports Q1 Revenue Growth - GuruFocus
Transcript: CytoSorbents Q1 2026 Earnings Conference Call - Yahoo Finance
Cytosorbents Corp reports results for the quarter ended March 31Earnings Summary - TradingView
Cytosorbents Corp 1Q 2026: Revenue $8.86M, EPS ($0.08) — 10-Q Summary - TradingView
CYTOSORBENTS ($CTSO) Releases Q1 2026 Earnings - Quiver Quantitative
CytoSorbents (CTSO) posts wider Q1 2026 loss and flags going-concern risk - Stock Titan
CytoSorbents (NASDAQ: CTSO) details DrugSorb-ATR FDA path and Q1 2026 results - Stock Titan
CytoSorbents: Q1 Earnings Snapshot - marketscreener.com
CytoSorbents Reports First Quarter 2026 Financial Results, Recent Business Highlights, and Regulatory Update - Fidelity
CytoSorbents Q1 earnings preview - MSN
Cytosorbents Corp expected to post a loss of 5 cents a shareEarnings Preview - TradingView
CytoSorbents Announces HotSwap™ Launch, Renewed Aferetica Partnership, and New Clinical Evidence at ISICEM 2026 - Quantisnow
CTSO (Cytosorbents) revenue climbs 4.1% to $37.1M in Q1 but loss widens, shares flat.Earnings Yield Analysis - Newser
CytoSorbents to Report First Quarter 2026 Financial Results and Recent Business Highlights - BioSpace
CTSO Cytosorbents shares climb 6 percent today despite reporting a wider than expected Q4 2025 per share loss.Mid-Term Outlook - thelegaladvocate.com
CytoSorbents Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights - Aktiellt
CTSO Analyst Rating Update: HC Wainwright Lowers Price Target | - GuruFocus
Executive Compensation, Stock Options, and Corporate Governance Disclosure - Minichart
Governance, pay and ownership detailed in CytoSorbents (NASDAQ: CTSO) 10-K/A - Stock Titan
CytoSorbents Receives Nasdaq Extension to Regain Compliance - The Globe and Mail
CytoSorbents implemented workforce and cost reduction program - TipRanks
Cytosorbents Corp Azioni (CTSO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):